entete

Les publications du Dr Olivier Boucherat

2019

  1. Bonnet S, Boucherat O, Paulin R, Wu D, Hindmarch CCT, Archer SL, Song R, Moore JB 4th, Provencher S, Zhang L, Uchida S. Clinical values of non-coding RNAs in cardiovascular, pulmonary, and muscle diseases. Am J Physiol Cell Physiol. 2019 Sep 4.
  2. Ranchoux B, Nadeau V, Bourgeois A, Provencher S, Tremblay É, Omura J, CotĂ© N, Abu-Alhayja'a R, Dumais V, Nachbar RT, Tastet L, Dahou A, Breuils-Bonnet S, Marette A, Pibarot P, Dupuis J, Paulin R, Boucherat O, Archer SL, Bonnet S, Potus F. Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease. Circ Res. 2019 Aug 2;125(4):449-466.
  3. Bourgeois A, Bonnet S, Breuils-Bonnet S, Habbout K, Paradis R, Tremblay E, Lampron MC, Orcholski ME, Potus F, Bertero T, Peterlini T, Chan SY, Norris KA, Paulin R, Provencher S, Boucherat OInhibition of CHK1 (Checkpoint kinase 1) elicits therapeutic effects in pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2019 Aug;39(8):1667-1681.
  4.  Van der Feen DE, Kurakula K, Tremblay E, Boucherat O, Bossers GP, Szulcek R, Bourgeois A, Lampron MC, Habbout K, Martineau S, Paulin R, Kulikowski E, Jahagirdar R, Schalij I, Bogaard HJ, Bartelds B, Provencher S, Berger RMF, Bonnet S, Goumans MJ. Multicenter preclinical validation of BET inhibition for the treatment of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2019 May 1

2018

  1. Clemenceau A, Boucherat O, Landry-Truchon K, Lamontagne M, Biardel S, Joubert P, Gobeil S, Secco B, Laplante M, Morissette M, Obeidat M, Timens W, Jeannotte L, BossĂ© Y. Lung cancer susceptibility genetic variants modulate HOXB2 expression in the lung. Int J Dev Biol. 2018;62(11-12):857-864.
  2. Bonnet S, Paulin R, Boucherat OSmall SeP or giant leap for Pulmonary Hypertension Research? Circulation. 2018 Aug 7;138(6):624-626
  3. Bourgeois A, Omura J, Habbout K, Bonnet S, Boucherat OPulmonary arterial hypertension: New pathophysiological insights and emerging therapeutic targets. Int J Biochem Cell Biol. 2018 Sep 3;104:9-13.
  4. Provencher S, Archer SL, Ramirez FD, Hibbert B, Paulin R, Boucherat O, Lacasse Y, Bonnet S. Standards and methodological rigor in pulmonary arterial hypertension preclinical and translational researchCirculation Research. 2018 Mar 30;122(7):1021-1032
  5. Bonnet S and Boucherat OThe ROS controversy in hypoxic pulmonary hypertension revisited. Eur Respir J. 2018 Mar 8;51(3). pii:1800276
  6. Boucherat O, Peterlini T, Bourgeois A, Nadeau V, Breuils-Bonnet S, Boilet-Molez S, Potus F, Meloche J, Chabot S, Lambert C, Tremblay E, Chae YC, Altieri DC, Sutendra G, Michelakis ED, Provencher S, Bonnet S. Mitochondrial HSP90 accumulation promotes vascular remodeling in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine. 2018 Jul 1;198(1):90-103.
  7. Nadeau V, Potus F, Boucherat O, Paradis R, Tremblay E, Iglarz M, Paulin R, Bonnet S, Provencher S. Dual ETA/ETB blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension. Pulmonary Circulation. 2018 Jan-Mar;8(1)
  8. Bourgeois A, Lambert C, Habbout K, Paquet-Marceau S, Trinh I, Breuils-Bonnet S, Paradis R, Nadeau V, Paulin R, Provencher S, Bonnet S, Boucherat OFOXM1 promotes pulmonary smooth muscle cell expansion in pulmonary arterial hypertension. J Mol Med (Berl) 2018 Feb;96(2):223-235. 

2017

  1. Boucherat O, Provencher S, Bonnet S. Therapeutic Value of ASK1 in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2017 Sep 20
  2. Landry-Truchon K, Houde N, Boucherat O, Joncas FH, Dasen JS, Philippidou P, Mansfield JH, Jeannotte L. HOXA5 plays tissue-specific roles in the developing respiratory system. Development. 2017 Oct 1; 144(19):3547-3561
  3. Boucherat O, Chabot s, Paulin R, Trinh I, Bourgeois A, Potus F, Lampron MC, Lambert C, Breuils-Bonnet S, Nadeau V, Paradis R, Goncharova EA, Provencher S, Bonnet S. HDAC6: A novel histone deacetylase implicated in pulmonary arterial hypertension. Sci. Rep. 2017 Jul 3;7(1):4546
  4. Boucherat O, Vitry G, Trinh I, Paulin R, Provencher S, Bonnet S. The cancer theory of pulmonary arterial hypertension. Pulm. Circ. 2017 Apr-Jun;7(2):285-289
  5. Meloche J, Lampron MC, Nadeau V, Maltais M, Potus F, Lambert C, Tremblay E, Vitry G, Breuils-Bonnet S, Boucherat O, Charbonneau E, Provencher S, Paulin R, Bonnet S. Implication of inflammation and epigenetics Readers in Coronary Artery Remodeling in patients with pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):1513-1523. 
  6. Boucherat O, Landry-Truchon K, Aoidi R, Houde N, Nadeau V, Charron J, Jeannotte L. Lung development requires and active ERK/MAPK pathway in the lung mesenchyme. Dev Dyn. 2017 Jan;246(1):72-82. 
  7. Bonnet S, Provencher S, Guignabert C, Perros F, Boucherat O, Schermuly RT, Hassoun PM, Rabinovitch M, Nicolls MR, Humbert M. Translating research into improved patient care in pulmonary arterial hypertension. Am J Resp Crit Care Med. 2017 Mar1;195(5):583-85 

2016

  1. Boucherat O, Bonnet S and Paulin R. The HIPPO-thesis of pulmonary HYPERtension. Am J Resp Crit Care Med. 2016 Oct 1;194(7):787-9
  2. Ranchoux B*, Meloche J*, Paulin R, Boucherat O, Provencher S, Bonnet S. DNA damage and pulmonary hypertension. International Journal of Molecular Sciences. 2016 Jun 22;17(6).
  3. Boucherat O, Bonnet SMicroRNA signature of End-Stage idiopathic pulmonary arterial hypertension: Clinical correlations and regulation of WNT signaling. Journal of Molecular Medicine (Berlin). 2016 Aug;94(8):849-51
  4. Ruffenach*, Chabot S*, Tanguay VF, Courboulin A, Boucherat O, Potus f, Meloche J, Pflieger A, Breuils-Bonnet S, Nadeau V, Paradis R, Girerd B, Hautefort A, Montani D, Fadel E, Dorfmuller P, Humbert M, Perros F, Paulin R, Provencher S, Bonnet SRUNX2 in proliferative and calcified vascular lesions seen in pulmonary arterial hypertension. Am J Resp Crit Care Med. 2016 Nov15;194(10):1273-1285
  5. Boucherat O, Morissette MC, Provencher S, Bonnet S, Maltais F. Bridging lung development with COPD: Relevance of developmental pathways in COPD pathogenesis. Am J Respir Crit Care Med. 2016 Feb 15;193(4):362-75
  6. Boucherat O, Jeannotte L, Hadchouel A, Delacourt C, Benachi A. Pathomechanismms of congenital cystic lung diseases: Focus on congenital cystic adenomatoid malformation and pleuropulmonary blastoma. Paediatr. Respir Rev. 2016 Jun;19:62-8.

2015

  1. Boucherat O, Potus F, Bonnet S. microRNA and Pulmonary HypertensionAdv Exp Med Biol. 2015;888:237-52
  2. Boucherat O, Chabot S, Antigny F, Perros F, Provencher S, Bonnet S. Potassium channels in pulmonary arterial hypertension. Eur Respir J. 2015 Oct;46(4):1167-77. Review.
  3. Boucherat O, Bonnet S. NOGGIN: a new therapeutic target for PH? Focus on “Noggin inhibits hypoxia-induced proliferation by targeting store-operated calcium entry and TRPC channels”. Am J Physiol Cell Physiol. 2015 Jun1;308(11):C867-8
  4. Boucherat O, Landry-Truchon K, BĂ©rubĂ©-Simard FA, Houde N, Beuret L, Lezmi G, Foulkes WD, Delacourt C, Charron J, Jeannotte L. Epithelial inactivation of Yy1 abrogates lung branching morphogenesis. (ERRATUM) Development. 2015 Sep 1;142(17):22981-95.

2014

  1. Boucherat O, Landry-Truchon K, BĂ©rubĂ©-Simard FA, Houde N, Beuret L, Lezmi G, Foulkes WD, Delacourt C, Charron J, Jeannotte L. Epithelial inactivation of Yy1 abrogates lung branching morphogenesis. Development 2014 August;141(16):3197-211.

2013

  1. Boucherat O, Boczkowski J, Jeannotte L, Delacourt C. Cellular and molecular mechanisms of goblet cell metaplasia in the respiratory airways. Exp Lung Res. 2013 May-Jun;39(4-5):207-16.
  2. Boucherat O, Montaron S, BĂ©rubĂ©-Simard FA, Aubin J, Philippidou P, Wellik DM, Dasen JS, Jeannotte L. Partial functional redundancy between Hoxa5 and Hoxb5 paralog genes during lung morphogenesis. Am J Physiol Lung Cell Mol  Physiol. 2013 Jun 15;304(12):L817-30

2012

  1. Boucherat O, Chakir J, Jeannotte L. The loss of Hoxa5 function promotes Notch-dependent goblet cell metaplasia in lung airways. Biol Open. 2012 Jul 15;1(7):677-91
  2. Gendronneau G, Boucherat O, Aubin J, Lemieux M, Jeannotte L. The loss of Hoxa5 function causes estrous acyclicity and ovarian epithelial inclusion cysts. Endocrinology. 2012 Mar;153(3):1484-97 

2011

  1. Franco-Montoya ML, Boucherat O, Thibault C, Chailley-Heu B, Incitti R, Delacourt C, Bourbon JR. Profiling target genes of FGF18 in the postnatal mouse lung: possible relevance for alveolar development. Physiol. Genomics. 2011 Nov 7;43(21):1226-40. 

2010

  • Coulombe Y, Lemieux M, Moreau J, Aubin J, Joksimovic M, BĂ©rubĂ©-Simard FA, Tabariès S, Boucherat O, Guillou F, Larochelle C, Tuggle CK, Jeannotte L. Multiple promoters and alternative splicing: Hoxa5 transcriptional complexity in the mouse embryoPLoS One. 2010 May 12;5(5):e10600
  • Boucherat O, Franco-Montoya ML, Delacourt C, Martinovic J, Masse V, Elie C, ThĂ©baud B, Benachi A, Bourbon JR. Defective angiogenesis in hypoplastic human fetal lungs correlates with nitric oxide synthase deficienccy that occurs despite enhanced angiopoietin-2 and VEGF. Am J Physiol Lung Cell Mol Physiol. 2010 Jun;298(6):L849-56.

2009

2008

  • MĂ©hats C, Franco-Montoya ML, Boucherat O, Lopez E, Schmitz T, Zana E, Evain-Brion D, Bourbon J, Delacourt C, Jarreau PH. Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats. PLoS One. 2008;3(10):e3445.
  • Hadchouel A, Decobert F, Franco-Montoya ML, Halphen I, Jarreau PH, Boucherat O, Martin E, Benachi A, Amselem S, Bourbon J, Danan C, Delacourt C. Matrix metalloproteinase gene polymorphisms and bronchopulmonary dysplasia: identification of MMP16 as a new player in lung development. PLoS One. 2008 Sep 11;3(9):e3188.

2007

  • Boucherat O, Franco-Montoya ML, Thibault C, Incitti R, Chailley-Heu B, Delacourt C, Bourbon JR. Gene expression profiling in lung fibroblasts reveals new players in alveolarization. Physiol Genomics. 2007 Dec 19;32(1):128-41.
  • Boucherat O, Benachi A, Chailley-Heu B, Franco-Montoya ML, Elie C, Martinovic J, Bourbon JR. Surfactant maturation is not delayed in human fetuses with diaphragmatic hernia. PLoS Med. 2007 Jul 31;4(7):e237.
  • Waszak P, Franqueville L, Franco-Motoya ML, Rosa-Calatrava M, Boucherat O, Lindholm L, Delacourt C, Boulanger P. Toxicity of fiber- and penton base-modified adenovirus type 5 vectors on lung development in newborn rats. Mol Ther. 2007 Nov;15(11):2008-16. 
  • Boucherat O, Bourbon JR, Barlier-Mur AM, Chailley-Heu B, D'Ortho MP, Delacourt C. Differential expression of matrix metalloproteinases and inhibitors in developing rat lung mesenchymal and epithelial cells. Pediatr Res. 2007 Jul;62(1):20-5.
  • Boucherat O, Benachi A, Barlier-Mur AM, Franco-Montoya ML, Martinovic J, ThĂ©baud B, Chailley-Heu B, Bourbon JR. Decreased lung fibroblast growth factor 18 and elastin in human congenital diaphragmatic hernia and animal models. Am J Respir Crit Care Med. 2007 May 15;175(10):1066-77.

2006

2005

© 2012 Université Laval. Tous droits réservés